Navigation Links
Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
Date:5/14/2008

BRISBANE, Australia, May 14 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX:PGL; Nasdaq: PGLA) today announced that the Company has resumed patient enrolment in the phase 1 dose-escalation study of its recently acquired polyamine analogue, PG-11047 (formerly CGC-11047) for patients with advanced cancer.

Progen has commenced development of PG-11047 - the lead clinical compound in the Company's polyamine program - following its acquisition of Cellgate, Inc earlier this year. The first patient to be recruited into the trial re-initiation has been enrolled at the University of Chicago.

The trial is exploring the potential of PG-11047 as a single anti-cancer agent and is designed to assess the agent's maximum tolerated dose. Under CellGate, the trial had recruited 31 patients and had shown little evidence of toxicity, while using significantly higher doses than most previous studies of polyamine compounds.

Justus Homburg, Progen's CEO, said, "Since the acquisition of CellGate, we have been assessing our portfolio of clinical and pre-clinical compounds in order to determine which to drive forward. Our re-initiation of PG-11047 in phase 1 clinical development is the first step in driving potential value from our expanded portfolio of first-in-class oncology therapies."

Data from the trial will be used in parallel with a separate PG-11047 study assessing the agent in combination with other marketed anti-cancer drugs as the basis for determining potential phase 2 development. Progen expects the study to produce data within the next 12 months.

About Progen: Progen Pharmaceuticals is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has operations in Australia and the US.

About PG-11047: PG-11047 is a polyamine analogue which modifies the production of natural polyamines. Polyamines a
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
3. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
4. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
5. Progen Announces PI-88 Phase 2 Lung Cancer Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
11. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2009)...ewswire/ -- Patients reported C1-esterase inhibito...treating acute swelling attacks at any body locati...ccording to data presented today at the 2009 Ameri...CAAI) Annual Meeting. The results come from a self... with the ongoing, prospective, open label I nter...
(Date:11/6/2009)...re-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC...iously approved reverse split of its common stock ..., Nov. 9, 2009 on a 1-for-15 split-adjusted basis....der the new symbol OXBT. The stock also will have ...comes effective. ,, "This reverse split was ove...
(Date:11/6/2009)...ewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(&...at is developing and marketing Levulan(®) Pho... on patients with common skin conditions, announce...ficer, will present a corporate overview at the Me..., November 10, 2009 at 10:00 a.m. ET at the Hotel ...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Cancer Diagnosis May Tax Physical Mental Health 48369 1Cancer Diagnosis May Tax Physical Mental Health 48369 2Randall Terry 3A How Tillers Death and office Closing Can Help Propel Pro Life Movement Derail Sotomayor and Overturn Roe 3B Four Key Senators Will B 48366 1Randall Terry 3A How Tillers Death and office Closing Can Help Propel Pro Life Movement Derail Sotomayor and Overturn Roe 3B Four Key Senators Will B 48366 2A real time diagnosis for a treatable cancer 48363 1A real time diagnosis for a treatable cancer 48363 2
... 2007 /PRNewswire-FirstCall/ -- Shire plc,announce...estigational medication guanfacine extended releas...tive,alpha-2A-adrenoceptor agonist. These data fro...ies and two long-term phase III,open-label studies...iation (APA) annual meeting, demonstrated that GXR...
...s from Phase 1 Studies with Monoclonal Antibody,Ta...vide Further,Rationale for IL-9 Inhibition in Deve...d., May 24, 2007 /PRNewswire-FirstCall/ --,MedImmu...highlighting recent progress within the company,s ...rom two Phase 1 clinical,studies with its monoclon...
Other Medicine Technology:Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 2Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 3Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 4Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 5Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 6Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 7Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 8MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7
(Date:11/8/2009)...ook called "Preventing and Healing AIDS Throu... shows that AIDS is a result of multiple, repeated...mune system stressor agents, which can be either c...otional. , Oakland, CA (...2009, cell biologists, physicians, chemists and ot...
(Date:11/8/2009)...swire-USNewswire/ -- Today, the House of Represent...r, Smith, Ellsworth and Lipinski amendment to the ...2). The amendment maintains the current policy of ...nefits packages that include abortion. It clarifie...bility credits and those who do not, can with thei...
(Date:11/8/2009)...of H.R. 3961 to Secure the Stability of Medicare ...tatement Attributable to: J. James Rohack, M.D., P...o: http://www.newscom.com/cgi-bin/prnh/20081209/...e House health reform bill, which will help improv...d calls for swift passage of H.R. 3961 to secure t...
(Date:11/8/2009)... March of Dimes hosted ...o recognize prominent individuals who are celebrat...odels for March of Dimes commitment to improve the...November Prematurity Awareness Month campaign, cel... fight for preemies! ,, (Photo: http://www.ne...
(Date:11/7/2009)...), David A. Cook (GA), Louis J. Goodman (TX), Palm..., CHICAGO, Nov. 7 The...d five medical society executive leaders with achi... goals and ideals of the medical profession. The a...cy making meeting in Houston. ,, (Logo: http...
Breaking Medicine News(10 mins):Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:AMA Honors Medical Society Executives 2
...ulation highlights need for complete, unbiased inf... Belleville, Ill. (Vocus) November 19, 2008 ...eir healthcare options for 2009 should welcome new...ding provider of Social Security disability, finan...
... , - Enables Speech Communication Between St...introduces VoIP (Voice over Internet Protocol),to ...at succeeds the teleCARE,M system, which is widely...adjust their work according to the information. , ...
...chwabe, the manufacturer of,the Ginkgo extract EGb...t,allow a final conclusion on the potential of the...e of five studies that have been or are investigat... subjects (average,age on entry 79 years) receivin...
...who undergo weight-loss surgery, known as bariatri...weight may be at lower risk for pregnancy-related ...that can seriously affect the mother or her baby -...19 issue of JAMA. , , The findings are part...
...e Health Solutions,Inc. (Nasdaq: STRM ) announce...al year 2008 financial results for the period ende...ter the market closes. The Company will hold a,con...77) 356-5706 or,(706) 679-3820, or can listen via ...
... by contact with blood, respiratory secretion , ...first Chinese case of a tick-borne disease called ... person-to-person transmission of the disease, is ...an-to-human transmission of HGA. , HGA was identif...
Other Medicine News:Health News:New Medicare Advantage Marketing Rules Help People Make Informed Choices, Allsup Says, , 2Health News:New Medicare Advantage Marketing Rules Help People Make Informed Choices, Allsup Says, , 3Health News:New Medicare Advantage Marketing Rules Help People Make Informed Choices, Allsup Says, , 4Health News:Ascom Wireless Solutions Adds Voice to Their TeleCARE IP Solution 2Health News:Ginkgo Biloba for Prevention of Dementia 2Health News:Some Pregnancy-Related Complications Minimized for Women Who Have Had Weight-Loss Surgery 2Health News:Some Pregnancy-Related Complications Minimized for Women Who Have Had Weight-Loss Surgery 3Health News:Streamline Health to Announce Third Quarter of Fiscal Year 2008 Financial Results on Tuesday, December 2, 2008 2Health News:China Documents First Case of Tick-Borne Disease Spread 2
Spectra2000, 110V/60Hz
Model 410 Visible Spectrophotometer
...ter allows the user to quickly and accurately coun... digital counting or manual counting. An optional ...creasing magnification to 3.0X. The adjustable foc...ed or lowered. The lens also rotates a full 360 fo...
Accucount 2000 (230V/50Hz)
Medicine Products: